多奈哌齐联合司来吉兰治疗阿尔茨海默病的临床效果

Clinical efficacy of donepezil combined with selegilan in the treatment of Alzheimer’s disease

目的观察多奈哌齐联合司来吉兰治疗阿尔茨海默病(AD)的临床效果。方法选取2019年5月-2020年5月山东省新泰市人民医院收治的AD患者90例,采取随机数字表法分为观察组和对照组,每组45例,对照组给予司来吉兰治疗,观察组在对照组的治疗基础上给予多奈哌齐治疗。比较2组的临床疗效、治疗前后认知功能及不良反应。结果观察组临床总有效率高于对照组(91.11%vs.71.11%,χ^(2)=5.874,P=0.015);治疗28 d后,2组阿尔茨海默病评定量表—认知分量表(ADAS-Cog)评分均低于治疗前,简易智力状态检查量表(MMSE)评分均高于治疗前,且观察组ADAS-Cog评分低于对照组,MMSE评分高于对照组,差异均有统计学意义(P<0.01);2组不良反应总发生率比较差异无统计学意义(χ^(2)=0.212,P=0.645)。结论多奈哌齐联合司来吉兰治疗AD的临床疗效较好,可有效改善认知功能,且未增加不良反应,值得临床推广应用。

Objective To observe the clinical effect of donepezil combined with selegiline in the treatment of Alzheimer’s disease(AD).Methods A total of 90 cases of AD patients admitted to Xintai People’s Hospital in Shandong Province from May 2019 to May 2020 were selected.Using random number table method,they were divided into observation group and control group,with 45 cases in each group.The control group was given selegiline treatment,and the observation group was given donepezil treatment on the basis of the treatment of the control group.The clinical efficacy,cognitive function and adverse reactions of the two groups were compared before and after treatment.Results The total effective rate of the observation group was higher than that of the control group(91.11%vs.71.11%,χ^(2)=5.874,P=0.015).28 days after treatment,the scores of alzheimer’s disease rating scale-cognitive subscale(ADAS-COG)were lower than before treatment,the scores of simple mental state checklist(MMSE)were higher than before treatment,and the ADAS-COG score of observation group was lower than control group,and the MMSE score was higher than control group,the differences were statistically significant(P<0.01).There was no significant difference in the total incidence of adverse reactions between the two groups(χ^(2)=0.212,P=0.645).Conclusion Donepezil combined with selegiran has good clinical efficacy in the treatment of AD,which can effectively improve cognitive function without increasing adverse reactions,and is worthy of clinical promotion and application.